Risk management of metabolic disorders in the use of antipsychotics
Abstract
Cardio-metabolic risk factors and diabetes mellitus type 2 are highly prevalent in patients with schizophrenia. Decrease of metabolic risks associated with use of atypical antipsychotics is connected with the development of specialised programs. They can prevent and treat metabolic disorders. This article presents a comprehensive approach to the problem and proposes a solution to minimise the risk of metabolic disorders. The analysis dependence risk of formation of metabolic disorders with genetic factors, behavioral disorders, associated with schizophreniaand therapypresented in the article.
About the Authors
G. E. Mazo
ФГБУ «СПб НИПНИ им. В.М. Бехтерева» Минздрава России; СПбГУ
Russian Federation
Russian Federation
A. O. Kibitov
ФГБУ «ФМИЦПН им. В.П. Сербского» Минздрава России
Russian Federation
Russian Federation
References
1. Горобец Л.Н. Изменение массы тела у больных шизофренией и шизоаффективным расстройством в условиях длительной терапии атипичными антипсихотиками / Л.Н. Горобец // Журнал неврологии и психиатрии им. С.С. Корсакова. - 2008. - № 9. - С. 52-56
2. Горобец Л.Н. Нейроэндокринные дисфункции и нейролептическая терапия / Медпрактика-М. - 2007. - 312 с
3. Горобец Л.Н., Буланов В.С., Василенко Л.М. Метаболические расстройства у больных шизофренией в процессе терапии атипичными антипсихотическими препаратами // Журнал неврологии и психиатрии им. С.С. Корсакова. - 2012. - Т. 112. - №9. - С. 90-96
4. Консенсус группы организаций Здоровья Америки. Окружность талии и кардиометаболический риск / Ассоциация по профилактике ожирения и коррекции массы тела; Северо- Американская ассоциация по изучению ожирения; Общество по ожирению; Американское общество по проблемам питания; Американская диабетологическая ассоциация // Артериальная гипертензия. - 2007. - Т. 13, № 3. - С. 1-6.
5. Чазова И. Е. Метаболический синдром / Чазова И. Е., МычкаВ. Б. - М.: Медиа Медика. - 2004. - 168 с.
6. Allison D., Casey D. Antipsychotic induced weight gain: a review of the literature // Journal of Clinical Psychiatry. 2001. - Vol. 62 (suppl. 7). - P. 22-31
7. Allison D.B., Fontaine KR., Moonseong H., Mentore J.L., Cappelleri J.C., Chandler L.P et al. The distribution of Body Mass Index among Individuals with and without Schizophrenia // J Clin Psychiatry. -1999. - Vol. 60. - Р 215.
8. Alvarez-Jimenez M., Hetrick S., Gonzalez-Blanch C. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials // Psychiatry. - 2008. - Vol. 193. - Р 101-107.
9. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes// Journal of Clinical Psychiatry. - 2004. - Vol. 65. - P. 267-272.
10. Bak M, Fransen A, Janssen J, van Os J, Drukker M Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. PLoS ONE. - 2014. - Vol. 9. - Р 94-112.
11. Baptista T., Reyes D., Hernandez L. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation // Pharmacol. Biochem. Behav. 1999. - Vol. 62. - P. 409-417.
12. Bou Khalil R1. Metabolic syndrome in patients with schizophrenia independently from atypical antipsychotics intake//Presse Med. - 2012. - vol. - Р 238-43. doi: 10.1016/j.lpm.2011.10.013.
13. Breier A., Berg P.H., Thakore J.H., et al. Olanzapine versus Ziprazidon: results of 28-week double-blind study in patients with schizophrenia //Am J Psychiatry - 2005 Oct. -162(10). - Р. 18791887.
14. Chen C., Chiu C., Huang M. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine // Prog Neuropsychopharmacol Biol Psychiatry - 2008.- Vol. 32. - Р. 925-931.
15. Connor W. N3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients / W. Connor, C. de Francesco, S. Connor // Annals of the New York Academy of Science. -1993. - Vol. 683. - P. 16-34.
16. Davidson J. Effectiveness of chromium in atypical depression: a placebo-controlled trial / J. Davidson, K. Abraham, K. Connor, M. McLeod // Biol. Psychiatry - 2003. - Vol. 53. - P. 261-264.
17. Davis J., Chen N., Glick I. A meta-analysis of the efficacy of second-generation antipsychotics // Arch Gen Psychiatry. - 2003. - Vol. 60. - P. 553-564.
18. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A. et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study // Clin Pract Epidemol Ment Health. - 2006. - Р 2-14.
19. Dent R., Blackmore A., Peterson J., Habib R., Kay G.P., Gervais A. et al. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature// PLoS One. - 2012. - Vol.7. - Р.368-389.
20. Dunn C., Peters D. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus // Drugs - 1995. - Vol. 49. - Р. 721-749.
21. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome// Lancet. - 2005. - Vol. 365. - Р. 1415-1428.
22. Edlinger M., HoferA., Rettenbacher M., etal. Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia // Schizophrenia Research. -2009. - Vol.113. - Р.246-251.
23. Emul M., Kalelioglu T. Etiology of cardiovascular disease in patients with schizophrenia: current perspectives // Neuropsychiatr Dis Treat. -2015. - Vol.1. - Р 2493-2503. doi: 10.2147/NDT. S50006. eCollection 2015.
24. Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Pro- gram (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) // JAMA. - 2001. - Vol. 285. - Р 2486-2497.
25. Frasure-Smith N. Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes // N. Frasure-Smith, F. Lesperance, P. Julien // Biol Psychiatry. - 2004. Vol. 55. - P. 891-896.
26. Gebhardt S., Theisen F.M., Haberhausen M., Heinzel-Gutenbrunner M., Wehmeier P.M., Krieg J.C., Kühnau W., Schmidtke J., Remschmidt H., Hebebrand J. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study// J Clin Pharm Ther. - 2010. - Vol. 35. - P. 207-211. doi: 10.1111/ j.1365-2710.2009.01084.
27. Gentile S., Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis // Drug Saf. - 2006. - Vol.29. - P. 303-319.
28. Goldman L.S. Medical illness in patients with schizophrenia//J Clin Psychiatry. - 1999. - Vol. 60. - P. 10-15.
29. Gough S.C., O’Donovan M.C. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? // J Psychopharmacol. 2005 - Vol. 19. - P. 47-55.
30. Green M., Marder S., Glynn S. The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone // Biol Psychiatry. - 2002. - Vol. 51. - P. 972-978.
31. Hadda P. Weight change with atypical antipsychotics in the treatment of schizophrenia // J. Psychopharmacol. - 2005. - Vol. 19. - P. 16-27.
32. Harrisson T.H. Scott L.J. Ziprazidon. A review of its Use in schizophrenia or schizoaffective disorder// CNS Drugs. - 2006. - №20. - P. 1028-1050.
33. Hasnain M., Fredrickson S., Vieweg W. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs // J Psychopharmacol. - 2011. - Vol. 25. - P. 715721.
34. Hasnain M., Vieweg W., Fredrickson S. Metformin for atypical antipsychoticinduced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions // CNS Drugs. - 2010. - Vol. 24. - P. 193-206.
35. Hasnaina M., ViewegW., Sonja V.R., Fredrickson K., Beatty-Brooks M., Fernandez A., Pandurangi A.K. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications// Primary care diabetes. - 2009. - Vol. 3 - P. 5-15.
36. Hegarty J., Baldessarini R., Tohen M. One hundred years of schizophrenia: a meta-analysis of the outcome literature // Am J Psychiatry - 1994. - Vol. 151. - P. 1409-1416.
37. Horacek J. The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers // Psychoneuroendocrinol. - 1999. - Vol. 24. - P. 785-787.
38. Hu G., Qiao Q., Tuomilehto J. et al. Prevalence of the metabolic syndrome and its relation to allcause and cardiovascular mortality in nondiabetic European men and women // Arch Intern Med. - 2004. - Vol. 164. - P. 1066-1076.
39. Kato M., Gonzalez-Blanco M., Sotelo J. et al. Metabolic syndrome in schizophrenia: a pilot study // American Psychiatric Association Annual Meeting. - 2003. - P. 211-213.
40. Kinon B.J., Lipkovich I., Edwards S.B. et al. A 24-week randomized study of olanzapine versus ziprazidon in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms // J Clin Psychpharmacol. - 2006. - Vol. 26. - P. 157-162.
41. Kris-Etherton P. Fish consumption, fish oil, omega-3 fatty acids and cardiovasculardisease / P. Kris-Etherton, W. Harris, L. Appel // Circulation. - 2002. - Vol. 106. - P. 2747-2757.
42. Kudla D., Lambert M., Domin S., Kasper S., Naber D. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial// European Psychiatry. - 2007. - №22. - P.195-202.
43. Lieberman J., Stroup T., McEvoy J. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia // N. Engl. J. Med. - 2005. - Vol. 353. - P. 1209-1223.
44. Malan-Müller S., Kilian S., van den Heuvel L.L., Bardien S., Asmal L., Warnich L., Emsley R.A., Hemmings S.M., Seedat S. A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia // Schizophr Res. 2016-Jan; 170(1) - P. 1-17. doi: 10.1016/j. schres. 2015.11.011
45. Malhotra N., Grover S., Chakrabarti S., Kulhara P. Metabolicsyndromeinschizophrenia. Indian // J Psychol Med. - 2013. - Jul-Sep. - 35(3) - P. 227-240.
46. Marinis T., Saleem P., Glue P. Switching to Long-Acting Injectable Risperidone is Beneficial with Regard to Clinical Outcomes, Regardless of Previous Conventional Medication in Patients with Schizophrenia // Pharmacopsychiatry. - 2007. - Vol. 40. - P. 257-263.
47. McLeod M. Chromium treatment of depression // M. McLeod, R. Golden // Int. J. Neuropsychopharmacol. - 2000. - Vol. 3. - P. 311-314.
48. Millar H. Management of physical health in schizophrenia: A stepping stone to treatment success // European Neuropsychopharmacology. - 2008. -18. - P. 121-128.
49. Müller D., Kennedy J. Genetics of antipsychotic treatment emergent weight gain in schizophre nia // Pharmacogenomics.- 2006 - Vol. 7. - P. 863-887.
50. Narula P., Rehan H., Unni K. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial // Schizophr Res. - 2010. - Vol. 118. - P. 218-223.
51. Nasrallah H. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles// Molecular Psychiatry. - 2008.- Vol. 13. - P.27-35.
52. National Institute for Clinical Excellence. Schizophrenia, Full national clinical guideline on core interventions in primary and secondary care. - 2008. http://www.nice.org.uk/page.aspx?o=42460
53. Newcomer J., Haupt D. The metabolic effects of antipsychotic medications // Can. J. Psychiatry. - 2006. - Vol. 51. - P.480-491.
54. Otanfio L.M., Izquierdoa L.B., Mondragon A.G., Pinedo M.A., Ayerdi I.Q. After six months of anti-psychotic treatment: Is the improvement in mental health at the expense of physical health? // Rev PsiquiatrSaludMent (Barc.). - 2013. - Vol.6. - P.26-32.
55. Park S., Lee J., Ha E., Choi S., Cho H., Seo M., Kim Y. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells // EurNeuropsychopharmacol. - 2009. - Vol.19. - P. 356-362. doi: 10.1016/j. euroneuro.2008.12.012
56. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms // PharmacolTher. - 2010. - Vol.125. - P. 169-179.
57. Roberts L., Roalfe A., Wilson S., Lester H. Physical health care of patients with schizophrenia in primary care: a compara- tive study // Fam. Pract. - 2007. - Vol. 24. - P. 34-40.
58. Roffeei S.N., Reynolds G.P., Zainal N.Z., Said M.A., Hatim A., Aida.SA., Mohamed Z. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone // Hum Psychopharmacol. - 2014. - Vol. 29. - P. 38-45. doi: 10.1002/ hup.2366
59. Ross B, WardP., GlenI. Delayed vasodilatory response to methylnicotinate in patients with unipolar depressive disorder// J. Affect. Disord. - 2004. - Vol. 82. - P. 285-290.
60. Sârvâri A.K., Veréb Z., Uray I.P., Fésüs L., Balajthy Z. Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro. // BiochemBiophys Res Commun. - 2014. - Vol. 450. - P. 1383-1389. doi: 10.1016/j.bbrc.2014.07.005. Epub 2014 Jul 11
61. Sickert L., Müller D.J., Tiwari A.K., Shaikh S., Zai C., De Souza R., De Luca V., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Association of the alpha 2A adrenergic receptor - 1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans // Pharmacogenomics. - 2009. - Vol. 10. - P. 1169-1176. doi: 10.2217/pgs.09.43
62. Simpson G.M., Weiden P.J., Pigott T., et al. Six-months blind multicenter continuation study of ziprazidon versus olanzapine in schizophrenia // Am J Psychiatry. - 2005. - Vol. 162. - P. 1535-1538.
63. Stengard J.H., KardiaS.L., HamonS.C. et al. Contribution of regulatory and structural variations in APOE to predicting dyslipidemia // J. Lipid. Res. - 2006. - Vol. 47. - P. 318-328.
64. Talmud P.J., HaweE., MartinS. et al. Relative contribution of variation within the APOC3/A4/ A5 gene cluster in determining plasma triglycerides // Hum. Mol. Genet. - 2002. - Vol. 11. - P. 3039-3046.
65. Weber M., Gutierrez AM. et al. The Risk sand Benefit sof Switching Antipsychotics: A Case Study Approach Perspectives // Psychiatric Care. 2009. - Vol. 45. - № 1. - January. - P. 54-61.
66. Weiden P.J., Buckley P.F. Reducing the burden of side effects during long-term antipsychotic therapy: the role of «switching» medications // J ClinPsychi atry. - 2007.- Vol.68. - P. 14-23.
67. Weiden P. J. Switching antipsychotics: An updated review with a focus on quetiapine // Journal of Psy chopharmacology. - 2006. - Vol. 20. - P. 104-118.
68. Woodward N., Purdon S., Meltzer H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects // Schizophr Res. - 2007. - Vol. 89. - P. 211-224.
69. Zimmermann U. et al. Epidemiology, implicatio ns and mechanisms under lyingdrug-induced weightg ain in psychiatric patients // Journal of Psychiatric Research. - 2003. - Vol. 37. - P. 193-220.
Review
For citations:
Mazo G.E., Kibitov A.O. Risk management of metabolic disorders in the use of antipsychotics. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2016;(3):85-97. (In Russ.)
Views:
482
Email this article 